Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp. > Financing in the 20s? Got to be low on cash
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(396)
•••
Comment by moneywagonon Nov 10, 2021 1:37pm
34 Views
Post# 34110999

RE:RE:RE:Financing in the 20s? Got to be low on cash

RE:RE:RE:Financing in the 20s? Got to be low on cash
palmpilot wrote: Sorry dude I have been here since the switch from Lion's Bay  to Biov at .22 cents. We even received a free 2 for 1 forward split share . So I guess my original cost was .11.

TRIPLE congrats !!!!! Yup I hold a few stocks single digit entries with years invested nice gains accumulation$$
It's great when you pull your capital off on the high and accumulate with only company green gains.. lol now that's the secret. Stocks to trade and stocks to keep!!  
I'm going to have to read up on Lions Bay for shytes n giggles!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities